Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue
+1.33%
EPS
+418.2%
Free cash flow
−6.83%
Total debt
−42.2%

Quarter to June 2026, against a year earlier

72.75 0.09 +0.12%
Market cap
$11.4B
P/E
62.2×
Fwd P/E
54.2×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100

Bio-Techne Corp (TECH) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Bio-Techne Corp (TECH) trades at a P/E ratio of 62.2×. Over the past ten years it has ranged from 28.5× (January 2015) to 148× (September 2021); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 10.3× and above the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2026 60.4× (46.01%)
FY2025 112× 65.56%
FY2024 67.6× 50.62%
FY2023 44.9× (10.20%)
FY2022 49.9× (59.73%)
FY2021 124× 181.83%
FY2020 44.0× (46.79%)
FY2019 82.7× 86.38%
FY2018 44.4× (26.36%)
FY2017 60.3× 50.19%

Quarterly newest first

Period P/E ratio Change
Jun 2026 60.4× (17.96%)
Mar 2026 73.6× (34.92%)
Dec 2025 113× 1.65%
Sep 2025 111× (0.53%)
42 more quarters

Against its own ten years

Low 28.5× High 148×
Ten-year median 54.6×
Current reading's percentile 59

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on TECH